Cervical Intraepithelial Neoplasia-Predictive Molecular Growth Factors in Natural History

Robert Jach1*, Bartłomiej Galarowicz1, Klaudia Stangiel-Wójcikiewicz1, Tomasz Banaś1, Joanna Streb1, Artur Ludwin1, Inga Ludwin1 and Grzegorz Dyduch1

1Jagiellonian University Medical College, Department of Gynecologic Oncology, 23 Kopernika str, 31-501 Krakow, Poland
2Jagiellonian University Medical College, Department of Clinical Oncology, 10 Śniadeckich str, 31-501 Krakow, Poland
3Jagiellonian University Medical College, Department of Pathology, 16 Grzegórzecka str, 31-501, Krakow, Poland

Abstract

There is considerable controversy regarding the possible over-treatment of patients with mild Cervical Intraepithelial Neoplasia (CIN), with lesions being often excised or ablated. Thus, identifying the markers of potentially malignant lesions would be of a great prognostic value. In the current study, we hypothesized that using colposcopic, cytolological and histological findings together with assessing the expression of molecular growth factors can predict CIN outcome. The study group consisted of 285 women between 19 and 81 years of age (median age, 37.8 years). The follow up were 60 months and considered 138 women: 50 women with Subclinical Papillomavirus Infection (SPI), 50 women with CIN1 and 38 women with CIN2.

All patients underwent cytology, colposcopy, and sampling for subsequent testing for HPV. In cases in which colposcopy suggested the presence of suspicious lesions, biopsy specimens were taken. HPV DNA was genotyped for HPV types 16, 18, 31, 33, and 45 by multiplex PCR. Transcripts of HR HPV types 16, 18, 31, 33, and 45 were detected by the NucliSens EasyQ HPV assay. The VEGF expression was analyzed with immunohistochemistry, RNA extraction, cDNA synthesis and RT-PCR analysis and Western blot.

We found that so called lymphangiogenetic switch (over expression of VEGF C and VEGFR-2) appears already in CIN 2, which is a rare observation, Persistent HPV HR infection is not only a trigger but also a maintenance factor in the cervical carcinogenesis. CIN2/3 and cervical cancer is in high percentage associated with the presence of HR DNA HPV as well as E6/E7 DNA mRNA. In CIN2/3 and cervical cancer VEGF and its receptor expression correlate with the stage of cervical carcinogenesis.

In CIN2/3 and cervical cancer progression of cervical intraepithelial neoplasia occurs when co expression of all: HR DNA HPV, E6/E7 HR HPV mRNA and VEGF is present.

Keywords: CIN (Cervical intraepithelial neoplasia); Cervical cancer; VEGF; VEGFR; DNA HPV; mRNA E6/E7 HPV

Introduction

Cervical cancer is the second most common cancer in women and the leading cause of cancer-related death in females from underdeveloped countries. Each year, approximately 500,000 cases of cervical cancer are diagnosed worldwide.

Routine screening has decreased the incidence of invasive cervical cancer in the United States, where approximately 13,000 cases of invasive cervical cancer and 50,000 cases of cervical carcinoma in situ (i.e. true precancer) are diagnosed annually [1].

Cervical cancer arises from the metaplastic epithelium of the Transformation Zone (TZ) (squamocolumnar junction) and develops slowly through progressive dysplastic changes to Carcinoma In Situ (CIS) and invasive cancer. Cervical Intraepithelial Neoplasia (CIN) is divided into three stages according to the degree of epithelial dysplasia and differentiation. Lesions are accessible to colposcopic evaluation and biopsy, which makes monitoring disease progression relatively easy. Low grade lesions (i.e. CIN1) and, in some cases CIN2 may spontaneously regress or not progress further, while the malignant potential of CIN 3 is 36% over 20 years [2].

There is considerable controversy regarding the possible over-treatment of patients with mild cervical abnormalities, with lesions being often excised or ablated. Thus identifying the markers of potentially malignant lesions would be of great prognostic value [3].

The most common types of Human Papillomavirus (HPV) found in CIN and cervical patients are types 16, 18, 31, 33, and 45 [4]. Persistent infection with these types is regarded as the earliest carcinogenesis stage [5]. The role of HPV's in the etiology of cervical cancer is tightly correlated with the overexpression of two oncogenes (E6 and E7) due to a specific opening in the E2 open reading frame in the integrated viral genome [6]. Studies of cervical cancer cell lines and cancer biopsy specimens have shown that the continuous expression of these genes is a necessary condition for the transformation and maintenance of neoplastic and dysplastic cells [7-10].

In recent years, many studies have shown that testing for HPV DNA can improve the detection of High-Grade Squamous Intraepithelial Lesions (HSILs) and cervical cancer [8-12]. This suggests that DNA testing can make a useful contribution to the triage of women with...
an equivocal cytology finding and for follow-up after the treatment of precursor lesions. However, the high prevalence of transient and asymptomatic HPV infections means that DNA tests have low sensitivities. Identification of the persistent infections likely to produce high-grade lesions currently requires repeated monitoring of the HPV DNA types. Commercial nucleic acid sequence-based amplification in a real-time format allows the reliable type-specific detection of E6 and E7 mRNA from HPV types 16, 18, 31, 33, and 45. Several authors have thus suggested that RNA-based assays could be more effective than DNA testing in risk assessment [13-18].

The development of cervical cancer as well as other malignant tumors has conventionally been considered to follow a pre-vascular phase, where the growth of the primary tumor is restricted to a few millimeters in diameter due to the diffusion limit of oxygen [19]. Vascular Endothelial Growth Factor (VEGF) is one of the most specific and strongest growth factors for the endothelial cells among all the factors that have been discovered so far. VEGF, a multifunctional cytokine, stimulates angiogenic activity by increasing vascular permeability and acting as an endothelial cell mitogen. The protein family includes the following: VEGF- A [14], -B [15], -C [16], -D [17], -E [18] and placenta growth factor (PIGF) [20].

In this study, we evaluated the correlation between VEGF-C and VEGFR-2 and clinicopathologic parameters in cervical cancer.

In the current study, we hypothesized what using colposcopic, cytological and histological findings together with assessing the expression of molecular growth factors can predict CIN outcome.

Materials and Methods

Cervical specimens were collected from October 2006 to December 2007 from patients admitted for secondary screening to the Colposcopy Outpatient Service and the Gynecological Oncology Unit (Jagiellonian University Medical College, Krakow, Poland). The study group consisted of 285 women between 19 and 81 years of age (median age, 37.8 years).

In Poland the national screening for cervical cancer is an organized call-recall system with conventional Pap test as a screening tool. The triage for positive subject is colposcopy. The target population is women starting from 25 years of life, with 3 years interval. There are 16 regional centers serving as the colposcopy clinics, where colposcopy is performed. After colposcopy the subject is reffered to treatment or is referred back to her primary physician. The database of the screening program is centralized and linked to the national healthcare system.

The follow up period was 60 months and considered only 138 women of whom the informed consent was obtain for this type of observation. The distribution of the observed women was: 50 women with SPI, 50 women with CIN1 and 38 women with CIN2. The Ethics Committee of Jagiellonian University Medical College approved the study protocol recommending surgery instead of follow-up of women diagnosed with CIN3. Written informed consent was obtained from all participants. All participants received a self-administered questionnaire requesting personal data, a gynecologic history, and information on exposure to risk factors. Women undergoing previously treatment for invasive cervical cancer were excluded. All patients underwent cytology, colposcopy, and sampling for subsequent testing for HPV. In cases in which colposcopy suggested the presence of suspicious lesions, biopsy specimens were taken.

Follow up visits comprised of gynecological evaluation, Pap test, HPV sampling and colposcopy with cervical biopsy for histologic evaluation. The interval of visits was 6 months. The call-recall system was used. The SPI (subclinical papilloma infection) is a colposcopic term describing productive HPV infection, in which cytology presents koilocytosis or ASCUS results, and histology reveals no CIN but koilocytosis—presence of koilocytic epithelial cells with perinuclear halo containing HPV particles. The complete remission was defined as return to normal epithelium (no disease). The partial remission was defined as a step back in the sequence: normal, SPI, CIN1, CIN2 cervical tissue. The stationary state was defined as a persistency of SPI, CIN1 or CIN2 diagnosis during observation. The progression was defined as any step forward in the sequence: normal, SPI, CIN1, CIN2, CIN3, cervical cancer. All diagnosis i.e. SPI, CIN1 and CIN2 were based on histologic evaluation. Cytology was based on a conventional Pap smear. The cytological diagnosis was made by specialized cytopathologists using the Bethesda classification system. Colposcopy was performed by specialized gynecologists. The results were reported following guidelines issued by PSCCP (The Polish Society of Colposcopy and Cervical Pathophysiology), a member of EFC (European Federation of Colposcopy) and IF CPC (International Federation of Cervical Pathology and Colposcopy). Histology was performed with specimens collected by colposcopy-directed biopsy (traditional punch biopsy specimens) and/or cone specimens collected by the loop excision procedure. Histology results were obtained for all 138 patients.

Part of each tissue specimen was collected during surgery, one part for mRNA analysis - immediately frozen in RNAse later solution (Qiagen, Hilden, Germany), second part for protein analysis, both stored at -80°C until used for study. Cancer tissue preparation was done as reported by Molden et al. [21].

Cervical specimens for nucleic acid analyses were collected with a cervical brush by standard procedures. The material was preserved in PreservCyt/ThinPrep solution. Analyses were performed by the Virology Laboratory at the University Hospital, Krakow, Poland. HPV DNA was genotyped for HPV types 16, 18, 31, 33, and 45 by multiplex PCR.

Samples were analyzed for HPV E6 and E7 mRNA by real-time multiplex nucleic acid sequence-based amplification. Transcripts of HR HPV types 16, 18, 31, 33, and 45 were detected by the NucliSens EasyQ HPV assay (bioMerieux, Poland), according to the manufacturer’s instructions. The VEGF expression was analyzed with immunohistochemistry, RNA extraction, cDNA synthesis and RT-PCR analysis and Western blot analysis.

Using the Shapiro–Wilks test, the distributions of countinous variables in the examined groups of women were analyzed and the results were presented as median values (minimum–maximum). U Mann-Whitney test or Kruskal–Wallis analysis of variance, with post hoc test (when appropriate) were used as distribution of analyzed variables differed from the normal ones or were quantitative data were analyzed. A p value of 0.05 was accepted as statistically significant. All calculations were carried out with the use of STATISTICA software v.9.0. (StatSoft, USA 2009)

Result

Subclinical papilloma infection (SPI) and CIN outcome

(Table 1) 4–5-years clinical follow-up (cytologic-colposcopic) did not reveal statistically important differences in remission percentage of SPI women in comparison to CIN1 women. While remission was
The stationary status was statistically more frequently observed in women with CIN1 comparing to SPI women. Analogically, in cases of CIN2 the stationary status was observed more often comparing to SPI women. There were no statistically important differences between stationary status of women with CIN1 and CIN2. This may be the proof of non-stable, dynamic SPI characteristic, influenced by immunological factors. Such a concept may be also confirmed by higher SPI remission percentage in comparison to CIN1 and CIN2. Number of SPI, CIN1 and CIN2 was calculated in complete remission group and compared with the progression group (Yeats ch 2: p=0.024). There were no statistically difference between CIN1 and CIN2, between SPI and CIN, but there was statistically important difference between SPI and CIN 2 (p=0.006).

**Table 1: Comparison of SPI, CIN 1 and CIN 2 complete remission and progression.***

| Lesion | N | Complete remission | Progression |
|--------|---|--------------------|-------------|
|        | n | %                  | n | %          |
| SPI*   | 50 | 38                 | 6 | 12.0       |
| CIN 1  | 50 | 26                 | 9 | 18.0       |
| CIN 2* | 38 | 14                 | 12| 31.6       |
| Σ      | 138| 78                 | 27| 19.6       |

*statistical significance at p=0.006

The progression/remission analysis revealed that CIN 1 and CIN 2 remission and progression occurred in 78,2% cases, high risk (HR) and LR DNA HPV—in12,8% cases, and in 9% of women no DNA HPV was detected using HC2 test. While, the progression rate was the lowest in SPI (12,0%) women, and the highest in CIN2 (31,6%) cases, the progression in 96,3% of cases was accompanied with HR HPV DNA and only in one case (3,7%) with LR HPV DNA. These observations confirmed the importance of HR HPV DNA in cervical carcinogenesis. In the Table 1 the remainder was the cases of stationary state.

**Table 2: SPI, CIN 1 and CIN 2 remission and progression and E6/E7 HPV 16, 18, 31, 33 and 45 mRNA expression.**

| Lesion | n | Remission mRNA (+) | Progression mRNA (+) |
|--------|---|--------------------|----------------------|
|        | n | n | % | n | % | Σ | n | % | n | % | Σ |
| SPI    | 50 | 1 | 2,6| 37 | 97,4 | 38 | 4 | 66,7 | 2 | 33,3 | 30 |
| CIN 1  | 50 | 1 | 3,8 | 25 | 96,2 | 26 | 5 | 55,6 | 4 | 44,4 | 9  |
| CIN 2  | 38 | 0 | 0,0 | 14 | 100,0 | 14 | 11 | 91,7 | 1 | 8,3 | 12 |
| Σ      | 138| 2 | 2,6 | 76 | 97,4 | 78 | 20 | 74,1 | 7 | 25,9 | 27 |

**Discussion**

In this paper in the women with histologically diagnosed Subclinical Papillomavirus Infection (SPI), CIN1, CIN2, CIN3 and cervical cancer the epidemiological, morphological and molecular factors impacting cervical carcinogenesis were evaluated. In the subgroup of 138 women with SPI, CIN1 and CIN2 prospectively observed for 4-5 years, the importance of DNA HPV, E6/E7 HPV mRNA expression and VEGF expression as potential predictive factors were measured.

Despite of the fact, that the triggering factors in cervical carcinogenesis are pretty well studied [21] there are still gaps in the understanding of the mechanism, in which the CIN spontaneously regress, persists or progress into invasive cancer.

This is of special importance, because CIN in most cases affects women in their procreative life time. Own experience [22] and many other authors observations [23-28], revealed that SPI in nearly 80%, CIN1 in 40–60%, and CIN2 in 30–35% of cases spontaneously regress. So in these cases therapeutic approach is unnecessary. Similar findings reported Cox and Schifman in ALTS study [29]. In their study the DNA HPV, especially HR was related to higher percentage of SPI, CIN 1 and CIN2 progression to HSIL (CIN3+) (10%, 12,5% and 30,2% respectively). Similar findings reported Goldie et al. [30], Castle et al. [31], Ingsinga et al. [32] and Moore et al. [33].

According to many clinicians and molecular biologists E6/E7 mRNA HPV expression is the sign of persistent HPV infection [21,27,28]. Moscicki et al. [34] and Castle et al. [31] state, that HPV-16 persistency increases the risk of CIN3 development of 40% within 5 years. Both transcriptors E6 and E7 HPV HR are stimulating cell cycle. They inactivate p53 and pRB, and stimulate replication and activate telomerase.

**Table 3: VEGF (pg/ml) expression and SPI, CIN 1 and CIN 2 outcome.**

| Lesion | n | VEGF (pg/ml) expression |
|--------|---|------------------------|
|        | Min | Max | Me | Min | Max | Me |
| SPI    | 50 | 16,00 | 18,24 | 16,76** | 17,11 | 29,99 | 28,42** |
| CIN 1  | 50 | 17,12 | 19,11 | 17,98* | 21,89 | 31,21 | 29,12* |
| CIN 2  | 38 | 20,99 | 22,45 | 21,13* | 24,95 | 72,00 | 36,12* |
| Σ      | 138| 16,00 | 22,45 | 18,98* | 17,11 | 72,00 | 34,72** |

*p<0,001; **p<0,001; ***p<0,001; ***p<0,001; #p<0,001; #p<0,008; #p=0,039
The important issue in carcinogenesis studies is examining the neoangiogenesis. We found that so-called lymphangiogenetic switch (over expression of VEGF C and VEGFR-2) appears already in CIN2, which is an original observation. In fact Van Trappen et al. [35] fund in 78% CIN3 lesions moderate to strong expression of VEGF-C and VEGF-D, but in CIN1 and CIN2 only in single cases. In our study we stated that VEGF expression May be useful as a progression indicator in CIN2 to CIN3. This is one of the first reports of such an observation confirmed in prospective observations.

These observations confirm that VEGF is an important angiogenic factor in progression of cervical carcinoma and suggest molecular growth stimulation via VEGFR-2 in cervical carcinogenesis. Our results show that the switch to the lymphangiogenetic phenotype occurs prior to the stage of invasion and probably between CIN2 and CIN3, and blocking VEGF-2 signaling may represent a novel therapeutic approach to the treatment of a subset of cervix cancer and cervical intraepithelial neoplasia.

Conclusions

Persistent HPV HR infection is not only a trigger but also a maintenance factor in the cervical carcinogenesis.

In high percentage of CIN2/3 and cervical cancer cases HR DNA HPV and E6/E7 DNA mRNA are expressed.

In CIN2/3 and cervical cancer VEGF and its receptor expression correlate with the stage of cervical carcinogenesis.

Progression of cervical intraepithelial neoplasia occurs when co expression of at least one factor: HR DNA HPV, E6/E7 HR HPV mRNA or VEGF is present. It seems that the more than one of these factors are expressed the trend of progression is stronger.

We are aware that there are many reasons, some related to the process of screening why alternative explanation for the findings, including bias other than those we postulate could explain the findings.

References

1. http://www.iarc.fr
2. Ostör AG (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12: 186-192.
3. Muñoz N, Castellsagué X, de González AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 3: S3/1-10.
4. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73.
5. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
6. Lazo PA (1997) Papillomavirus integration: prognostic marker in cervical cancer? Am J Obstet Gynecol 176: 1121-1122.
7. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
8. Bulkmans NW, Berkhof J, Rozendal L, van Kemenade FJ, Boeke AJ, et al. (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
9. Bosch FX, de Sanjose S (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23: 213-227.
10. Schiffman M, Castle PE, Jorionno J, Rodríguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 367: 890-907.
11. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, et al. (2006) A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 118: 791-796.
12. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, et al. (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579-1588.
13. Cuschieri KS, Beattle G, Hassan S, Robertson K, Cubbe H (2005) Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods 124: 211-215.
14. Scheurer ME, Tortolero-Luna G, Guillaud M, Follen M, Chen Z, et al. (2005) Correlation of human papillomavirus type 16 and human papillomavirus type 18 e7 messenger RNA levels with degree of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 14: 1948-1952.
15. Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, et al. (2005) Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14: 367–372.
16. Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, et al. (2007) A cross-sectional study of a prototype carcinogenic human papillomavirus E6/ E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 13: 2599-2605.
17. Cuschieri KS, Whitley MJ, Cubbe HA (2004) Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. J Med Virol 73: 65-70.
18. Molden T, Nygård JF, Kraus I, Karlsen F, Nygård M, et al. (2005) Predicting CIN4 when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114: 973-976.
19. Folkman J, Hanahan D (1991) Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22: 339-347.
20. Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, et al. (2006) Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26: 2019-2026.
21. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B (2006) Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol 100: 95-100.
22. Jacob R, Kulinska-Litewka J, LAldier P, Szzudzrawa A, Kopera A, et al. (2010) Expression of VEGF, VEGF-C and VEGFR-2 in in situ and invasive SCC of cervix. Front Biosci (Elite Ed) 2: 411-423.
23. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285.
24. Herrero R, Castle PE, Schiffman M, Bratt MC, Hildesheim A, et al. (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191: 1796-1807.
25. Depuydt CE, Vereecken AJ, Salembier GM, Vanbrabant AS, Boels LA, et al. (2003) Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 88: 560-566.
26. Francisco Aguayo G (2012) There is Crossstalk between Human Papillomavirus and Cigarette Smoke Components for Cancer Development? J Carcinogene Mutagene 3: e105.
27. Varnai AD, Boldmann M, Bankfalvi A, Speich N, Schmitt C, et al. (2008) Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytopathologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 19: 457-465.
28. Bertuccio MP, Spataro P, Caruso C, Picerno I (2011) Detection of human papillomavirus E6/E7 mRNA in women with high-risk HPV types 16, 18, 31, 33 and 45 which are associated with the development of human cervical cancer. Eur J Gynaecol Oncol 32: 62-64.
29. Cox JT, Schiffman M, Solomon D; ASCUS-LSIL Triage Study (ALTS) Group (2003) Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188: 1406–1412.
30. Goldie SJ, Kohli M, Grina D, Weinstein MC, Wright TC, et al. (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96: 604-615.

31. Castle PE, Schiffman M, Wheeler CM, Solomon D (2009) Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113: 18-25.

32. Insinga RP, Dasbach EJ, Elbasha EH (2009) Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 9: 119.

33. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, et al. (2007) Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 197: 141.

34. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, et al. (2004) Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364: 1678-1683.

35. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, et al. (2003) Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554.